AbCellera Biologics (ABCL)
(Delayed Data from NSDQ)
$2.61 USD
+0.10 (3.98%)
Updated Aug 23, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for AbCellera Biologics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -146.40 | 158.52 | 153.46 | 118.92 | -2.21 |
Depreciation/Amortization & Depletion | 30.89 | 33.10 | 17.25 | 6.10 | 1.85 |
Net Change from Assets/Liabilities | 13.23 | 29.83 | 41.67 | -116.70 | 1.97 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 58.40 | 55.91 | 32.20 | 14.37 | 1.08 |
Net Cash From Operating Activities | -43.88 | 277.36 | 244.58 | 22.69 | 2.69 |
Property & Equipment | -76.95 | -70.66 | -58.45 | -9.67 | -4.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | -11.46 | -87.64 | 0.00 |
Investments | -168.91 | -296.40 | -294.96 | -19.25 | 0.00 |
Other Investing Activities | 24.75 | 14.43 | 32.62 | -3.22 | -1.78 |
Net Cash from Investing Activities | -221.11 | -352.63 | -332.25 | -119.78 | -5.78 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 0.00 | 4.62 | 598.50 | 0.01 |
Issuance (Repayment) of Debt | 11.59 | 2.43 | -0.95 | -4.45 | -0.21 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 89.60 | 0.39 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -1.23 | -4.06 | -7.55 | 0.00 | 0.00 |
Net Cash from Financing Activities | 10.36 | -1.63 | -3.89 | 683.65 | 0.20 |
Effect of Exchange Rate Changes | 0.59 | -9.60 | -1.43 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -254.04 | -86.49 | -92.97 | 586.56 | -2.89 |
Cash at Beginning of Period | 414.65 | 501.14 | 594.12 | 7.55 | 10.44 |
Cash at End of Period | 160.61 | 414.65 | 501.14 | 594.12 | 7.55 |
Diluted Net EPS | -0.51 | 0.50 | 0.48 | 0.45 | NA |
Fiscal Year End for AbCellera Biologics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -77.54 | -40.61 | -146.40 | -99.25 | -70.64 |
Depreciation/Amortization & Depletion | 44.80 | 6.77 | 30.89 | 21.79 | 14.38 |
Net Change from Assets/Liabilities | -35.02 | -26.98 | 13.23 | 11.82 | 4.66 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -3.92 | 19.12 | 58.40 | 41.38 | 27.44 |
Net Cash From Operating Activities | -71.67 | -41.71 | -43.88 | -24.27 | -24.16 |
Property & Equipment | -44.25 | -24.14 | -76.95 | -62.52 | -42.19 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 106.51 | 46.88 | -168.91 | -148.73 | -149.51 |
Other Investing Activities | 19.75 | 7.17 | 24.75 | 14.46 | 7.69 |
Net Cash from Investing Activities | 82.01 | 29.91 | -221.11 | -196.79 | -184.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.35 | 0.89 | 0.00 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | 4.50 | 2.12 | 11.59 | 7.64 | 0.64 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.37 | -0.19 | -1.23 | -1.05 | -0.68 |
Net Cash from Financing Activities | 5.48 | 2.83 | 10.36 | 6.59 | -0.04 |
Effect of Exchange Rate Changes | -0.82 | -0.78 | 0.59 | -0.48 | 0.58 |
Net Change In Cash & Equivalents | 14.99 | -9.75 | -254.04 | -214.94 | -207.61 |
Cash at Beginning of Period | 160.61 | 160.61 | 414.65 | 414.65 | 414.65 |
Cash at End of Period | 175.60 | 150.86 | 160.61 | 199.71 | 207.04 |
Diluted Net EPS | -0.13 | -0.14 | -0.16 | -0.10 | -0.11 |